Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MS Awareness Week

- PMLiVE

GW Pharma’s cannabis-based medicine to be tested in dementia

Trial will be funded by Alzheimer’s Research UK

Six factors that drive a multiple sclerosis patient’s choice of disease-modifying therapy

MS advocate Trishna Bharadia explains the numerous factors that lead patients to choose a disease-modifying therapy, including the important considerations healthcare professionals and pharma often forget.

Blue Latitude Health

Innovative approaches in the treatment of multiple sclerosis

Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon.

Blue Latitude Health

Living my best life with multiple sclerosis

Multi-award-winning advocate and patient engagement champion Trishna Bharadia gives a valuable insight into life with multiple sclerosis. She explains how treatment has changed, how our healthcare systems and pharma can...

Blue Latitude Health

- PMLiVE

Biogen files Tecfidera follow-up in the US

Improved GI tolerability is major selling point

- PMLiVE

Three key development areas in the management of multiple sclerosis

Last month, Mark Walker, our business development director, and Fabrice Allum, managing director of Porterhouse Insights, attended the ECTRIMS (European Committee for treatment and research in multiple sclerosis) congress in...

Porterhouse Medical Group

- PMLiVE

Ocrevus surge keeps Roche smiling in Q3

MS drug is performing well, but immuno-oncology contender is in the doldrums

- PMLiVE

Tackling a formidable foe

Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis

- PMLiVE

Novartis files for approval of MS drug in EU, US

Siponimod could achieve blockbuster status if approved, says analysts

Roche Basel Switzerland

Dismay as NICE rejects Roche’s MS drug Ocrevus

Treatment deemed too costly to treat primary progressive MS

Biogen Idec building

Biogen and AbbVie pull MS drug Zinbryta from the market

Potential risks of liver damage and immune-related conditions have been reported

Celgene building

FDA turns down Celgene’s filing for multiple sclerosis drug

The application needs additional pharmacology information according to the US agency

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links